Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Ltd has successfully completed the first surgical case using its Remplir™ nerve repair device in Hong Kong, marking a significant milestone in its Asia-Pacific commercialization strategy. The launch at the Hong Kong Orthopaedic Association’s Annual Congress, in partnership with local distributor MontsMed, positions Orthocell to penetrate the Greater Bay Area market, a region with substantial growth potential. With a strong financial position and strategic partnerships, Orthocell is poised to expand its global footprint and increase revenue, with upcoming sales in Canada and Thailand and continued momentum in the US market.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a medical technology company specializing in regenerative medicine, particularly focusing on nerve repair. Their flagship product, Remplir™, is a nerve repair medical device that is being commercialized across various global markets, including Australia, New Zealand, Singapore, the US, and Hong Kong, with plans to expand to Canada and Thailand.
Average Trading Volume: 741,094
Technical Sentiment Signal: Buy
Current Market Cap: A$315.6M
Learn more about OCC stock on TipRanks’ Stock Analysis page.